Mechanism of Action of the Angiostatic Cortisene Anecortave Acetate

Survey of Ophthalmology

Volumn 52, Issue 1 SUPPL., 2007, Pages

  Clark, Abbot F ^a  

^a ALCON RESEARCH LTD   (United States)

Author keywords

anecortave acetate, AL 3789; angiostatic agents; neovascularization; ocular angiogenesis

Indexed keywords

AL 4940; ALPHA INTERFERON; ANECORTAVE; ANECORTAVE DESACETATE; ANGIOGENESIS INHIBITOR; ANGIOGENIC FACTOR; ANGIOSTATIC CORTISENE; APTAMER; CELECOXIB; DEXAMETHASONE; DRUG METABOLITE; FLUOCINONIDE; GLUCOCORTICOID; HYDROCORTISONE; HYDROCORTISONE ACETATE; LY 333536; MATRIX METALLOPROTEINASE INHIBITOR; MIDOSTAURIN; NEPAFENAC; NONSTEROID ANTIINFLAMMATORY AGENT; PEGAPTANIB; PREDNISOLONE; PROTEIN KINASE C BETA INHIBITOR; PROTEIN KINASE C INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR; RANIBIZUMAB; RUBOXISTAURIN; SQUALAMINE; THALIDOMIDE; TRIAMCINOLONE ACETONIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN INHIBITOR;

ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; ARTICLE; CATARACT; CLINICAL TRIAL; DIABETIC MACULAR EDEMA; DRUG EFFICACY; DRUG TARGETING; ENDOPHTHALMITIS; HUMAN; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE ABNORMALITY; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; PAW EDEMA; PRIORITY JOURNAL; RETINA DETACHMENT; RETINA EDEMA; RETINA MACULA AGE RELATED DEGENERATION; RETINA NEOVASCULARIZATION; SUBCAPSULAR CATARACT; SUBRETINAL NEOVASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANIMALS; DRUG DESIGN; EYE; HUMANS; NEOVASCULARIZATION, PATHOLOGIC; PREGNADIENEDIOLS;

EID: 33846198154     PISSN: 00396257     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.survophthal.2006.11.003     Document Type: Article

References (64)

1. -. The effect of ruboxistaurin on visual loss in patients with moderately severe to very severe nonproliferative diabetic retinopathy: initial results of the Protein Kinase C beta Inhibitor Diabetic Retinopathy Study (PKC-DRS) multicenter randomized clinical. Diabetes 54 (2005) 2188-2197
2. -. Anti-vascular endothelial growth factor therapy for subfoveal choroidal neovascularization secondary to age-related macular degeneration: phase II study results. Ophthalmology 110 (2003) 979-986
3. -. Preclinical and phase 1A clinical evaluation of an anti-VEGF pegylated aptamer (EYE001) for the treatment of exudative age-related macular degeneration. Retina 22 (2002) 143-152
4. Aiello L.P. The potential role of PKC beta in diabetic retinopathy and macular edema. Surv Ophthalmol 47 Suppl 2 (2002) S263-S269
5. Aiello L.P. Vascular endothelial growth factor. 20th-century mechanisms, 21st-century therapies. Invest Ophthalmol Vis Sci 38 (1997) 1647-1652
6. Aiello L.P., Bursell S.E., Clermont A., et al. Vascular endothelial growth factor-induced retinal permeability is mediated by protein kinase C in vivo and suppressed by an orally effective beta-isoform-selective inhibitor. Diabetes 46 (1997) 1473-1480
7. Casey R., and Li W.W. Factors controlling ocular angiogenesis. Am J Ophthalmol 124 (1997) 521-529
8. Chrousos G.P., Barnes K.M., Sauer M.A., et al. Delta 1, 9(11)-11-deoxycortisol: an improved glucocorticoid antagonist. Endocrinology 107 (1980) 472-477
9. Ciardella A.P., Donsoff I.M., Guyer D.R., et al. Antiangiogenesis agents. Ophthalmol Clin North Am 15 (2002) 453-458
10. Ciardella A.P., Klancnik J., Schiff W., et al. Intravitreal triamcinolone for the treatment of refractory diabetic macular oedema with hard exudates: an optical coherence tomography study. Br J Ophthalmol 88 (2004) 1131-1136
11. Ciulla T.A., Criswell M.H., Danis R.P., et al. Squalamine lactate reduces choroidal neovascularization in a laser-injury model in the rat. Retina 23 (2003) 808-814
12. Ciulla T.A., Walker J.D., Fong D.S., et al. Corticosteroids in posterior segment disease: an update on new delivery systems and new indications. Curr Opin Ophthalmol 15 (2004) 211-220
13. Clark A. Preclinical Efficacy of Anecortave Acetate. Surv Ophthalmol 52 Suppl 1 (2007) S41-S48
14. Clark A.F., and Morrison J.C. Corticosteroid glaucoma. In: Morrison J.C., and Pollack I.P. (Eds). Glaucoma: Science and Practice (2002), Thieme Medical Publishers, Inc., New York 197-206
15. Crum R., Szabo S., and Folkman J. A new class of steroids inhibits angiogenesis in the presence of heparin or a heparin fragment. Science 230 (1985) 1375-1378
16. Cunningham E.T., Adamis A.P., Altaweel M., et al. A phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema. Ophthalmology 112 (2005) 1747-1757
17. D'Amato R.J., Lin C.M., Flynn E., et al. 2-Methoxyestradiol, an endogenous mammalian metabolite, inhibits tubulin polymerization by interacting at the colchicine site. Proc Natl Acad Sci USA 91 (1994) 3964-3968
18. D'Amico D.J., Goldberg M.F., Hudson H., et al. Anecortave acetate as monotherapy for treatment of subfoveal neovascularization in age-related macular degeneration: twelve-month clinical outcomes. Ophthalmology 110 (2003) 2372-2383 discussion 2384-5
19. D'Amico D.J., Goldberg M.F., Hudson H., et al. Anecortave acetate as monotherapy for the treatment of subfoveal lesions in patients with exudative age-related macular degeneration (AMD): interim (month 6) analysis of clinical safety and efficacy. Retina 23 (2003) 14-23
20. Danis R.P., Bingaman D.P., Jirousek M., et al. Inhibition of intraocular neovascularization caused by retinal ischemia in pigs by PKCbeta inhibition with LY333531. Invest Ophthalmol Vis Sci 39 (1998) 171-179
21. Das A., and McGuire P.G. Retinal and choroidal angiogenesis: pathophysiology and strategies for inhibition. Prog Retin Eye Res 22 (2003) 721-748
22. Das A., McLamore A., Song W., et al. Retinal neovascularization is suppressed with a matrix metalloproteinase inhibitor. Arch Ophthalmol 117 (1999) 498-503
23. DeFaller J.M., and Clark A.F. A new pharmacological treatment for angiogenesis. In: Taylor H.R. (Ed). Pterygium (2000), Kugler Publications, The Hague 159-181
24. Dorrell M., Uusitalo-Jarvinen H., Aguilar E., and Friedlander M. Ocular Neovascularization; Basic Mechanisms and Therapeutic Advances. Surv Ophthamol 52 Suppl 1 (2007) S3-S19
25. Engler C.B., Sander B., Koefoed P., et al. Interferon alpha-2a treatment of patients with subfoveal neovascular macular degeneration. A pilot investigation. Acta Ophthalmol (Copenh) 71 (1993) 27-31
26. Fotsis T., Zhang Y., Pepper M.S., et al. The endogenous oestrogen metabolite 2-methoxyoestradiol inhibits angiogenesis and suppresses tumour growth. Nature 368 (1994) 237-239
27. Frank R.N. Potential new medical therapies for diabetic retinopathy: protein kinase C inhibitors. Am J Ophthalmol 133 (2002) 693-698
28. Friedlander M., Brooks P.C., Shaffer R.W., et al. Definition of two angiogenic pathways by distinct alpha v integrins. Science 270 (1995) 1500-1502
29. Geroski D.H., and Edelhauser H.F. Transscleral drug delivery for posterior segment disease. Adv Drug Deliv Rev 52 (2001) 37-48
30. Gillies M.C., Kuzniarz M., Craig J., et al. Intravitreal triamcinolone-induced elevated intraocular pressure is associated with the development of posterior subcapsular cataract. Ophthalmology 112 (2005) 139-143
31. Gragoudas E.S., Adamis A.P., Cunningham E.T., et al. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 351 (2004) 2805-2816
32. Gragoudas E.S., Adamis A.P., Cunningham E.T., et al. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 351 (2004) 2805-2816
33. Grossniklaus H.E., Ling J.X., Wallace T.M., et al. Macrophage and retinal pigment epithelium expression of angiogenic cytokines in choroidal neovascularization. Mol Vis 8 (2002) 119-126
34. Ishida K., Yoshimura N., Mandai M., et al. Inhibitory effect of TNP-470 on experimental choroidal neovascularization in a rat model. Invest Ophthalmol Vis Sci 40 (1999) 1512-1519
35. Jeong J.W., Cha H.J., Yu D.Y., et al. Induction of membrane-type matrix metalloproteinase-1 stimulates angiogenic activities of bovine aortic endothelial cells. Angiogenesis 3 (1999) 167-174
36. Jobling A.I., and Augusteyn R.C. What causes steroid cataracts? A review of steroid-induced posterior subcapsular cataracts. Clin Exp Optom 85 (2002) 61-75
37. Jonas J., Heatley G., Spaide R., et al. Intravitreal triamcinolone acetonide and secondary ocular hypertension. J Glaucoma 14 (2005) 168-171
38. Jonas J.B., Degenring R.F., Kreissig I., et al. Intraocular pressure elevation after intravitreal triamcinolone acetonide injection. Ophthalmology 112 (2005) 593-598
39. Jonas J.B., Kreissig I., and Degenring R.F. Factors influencing visual acuity after intravitreal triamcinolone acetonide as treatment of exudative age related macular degeneration. Br J Ophthalmol 88 (2004) 1557-1562
40. Jonas J.B., Kreissig I., Hugger P., et al. Intravitreal triamcinolone acetonide for exudative age related macular degeneration. Br J Ophthalmol 87 (2003) 462-468
41. Kirkpatrick J.N., Dick A.D., and Forrester J.V. Clinical experience with interferon alfa-2a for exudative age-related macular degeneration. Br J Ophthalmol 77 (1993) 766-770
42. Krzystolik M.G., Afshari M.A., Adamis A.P., et al. Prevention of experimental choroidal neovascularization with intravitreal anti-vascular endothelial growth factor antibody fragment. Arch Ophthalmol 120 (2002) 338-346
43. Li W.W., Casey R., Gonzalez E.M., et al. Angiostatic steroids potentiated by sulfated cyclodextrins inhibit corneal neovascularization. Invest Ophthalmol Vis Sci 32 (1991) 2898-2905
44. Majka S., McGuire P., Colombo S., et al. The balance between proteinases and inhibitors in a murine model of proliferative retinopathy. Invest Ophthalmol Vis Sci 42 (2001) 210-215
45. McNatt L.G., Weimer L., Yanni J., et al. Angiostatic activity of steroids in the chick embryo CAM and rabbit cornea models of neovascularization. J Ocul Pharmacol Ther 15 (1999) 413-423
46. Ozkiriş A., and Erkiliç K. Complications of intravitreal injection of triamcinolone acetonide. Can J Ophthalmol 40 (2005) 63-68
47. Penn J.S., and Rajaratnam V.S. Inhibition of retinal neovascularization by intravitreal injection of human rPAI-1 in a rat model of retinopathy of prematurity. Invest Ophthalmol Vis Sci 44 (2003) 5423-5429
48. Penn J.S., Rajaratnam V.S., Collier R.J., et al. The effect of an angiostatic steroid on neovascularization in a rat model of retinopathy of prematurity. Invest Ophthalmol Vis Sci 42 (2001) 283-290
49. Poliner L.S., Tornambe P.E., Michelson P.E., et al. Interferon alpha-2a for subfoveal neovascularization in age-related macular degeneration. Ophthalmology 100 (1993) 1417-1424
50. Robinson M.R., Baffi J., Yuan P., et al. Safety and pharmacokinetics of intravitreal 2-methoxyestradiol implants in normal rabbit and pharmacodynamics in a rat model of choroidal neovascularization. Exp Eye Res 74 (2002) 309-317
51. Robinson M.R., Lee S.S., Kim H., et al. A rabbit model for assessing the ocular barriers to the transscleral delivery of triamcinolone acetonide. Exp Eye Res 82 (2006) 479-487
52. Rosenthal R., Wohlleben H., Malek G., et al. Insulin-like growth factor-1 contributes to neovascularization in age-related macular degeneration. Biochem Biophys Res Commun 323 (2004) 1203-1208
53. Saishin Y., Silva R.L., Saishin Y., et al. Periocular injection of microspheres containing PKC412 inhibits choroidal neovascularization in a porcine model. Invest Ophthalmol Vis Sci 44 (2003) 4989-4993
54. Seo M.S., Kwak N., Ozaki H., et al. Dramatic inhibition of retinal and choroidal neovascularization by oral administration of a kinase inhibitor. Am J Pathol 154 (1999) 1743-1753
55. Smith L.E., Kopchick J.J., Chen W., et al. Essential role of growth hormone in ischemia-induced retinal neovascularization. Science 276 (1997) 1706-1709
56. Smithen L.M., Ober M.D., Maranan L., et al. Intravitreal triamcinolone acetonide and intraocular pressure. Am J Ophthalmol 138 (2004) 740-743
57. Stupack D.G., and Cheresh D.A. Integrins and angiogenesis. Curr Top Dev Biol 64 (2004) 207-238
58. Suzuma K., Takahara N., Suzuma I., et al. Characterization of protein kinase C beta isoform's action on retinoblastoma protein phosphorylation, vascular endothelial growth factor-induced endothelial cell proliferation, and retinal neovascularization. Proc Natl Acad Sci USA 99 (2002) 721-726
59. Takeda A., Hata Y., Shiose S., et al. Suppression of experimental choroidal neovascularization utilizing KDR selective receptor tyrosine kinase inhibitor. Graefes Arch Clin Exp Ophthalmol 241 (2003) 765-772
60. Unsoeld A.S., Junker B., Mazitschek R., et al. Local injection of receptor tyrosine kinase inhibitor MAE 87 reduces retinal neovascularization in mice. Mol Vis 10 (2004) 468-475
61. Wheeler G.D. Ruboxistaurin (Eli Lilly). IDrugs 6 (2003) 159-163
62. Witmer A.N., Vrensen G.F., Van Noorden C.J., et al. Vascular endothelial growth factors and angiogenesis in eye disease. Prog Retin Eye Res 22 (2003) 1-29
63. Yamamoto T., Terada N., Nishizawa Y., et al. Angiostatic activities of medroxyprogesterone acetate and its analogues. Int J Cancer 56 (1994) 393-399
64. Yasukawa T., Hoffmann S., Eichler W., et al. Inhibition of experimental choroidal neovascularization in rats by an alpha(v)-integrin antagonist. Curr Eye Res 28 (2004) 359-366